Circulation

One-year access to more than 500 world journals available in the system

Duration of Time : 365 Day
~~Price : 300$~~
Special Price : 100$

Order

A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone

Markus Meyer, Martin M. LeWinter, Michael R. Zile

doi : 10.1161/CIRCULATIONAHA.121.056412

Circulation. 2021;144:1269–1271

Buy The Package and View The Article Online

Social Vulnerability and Premature Cardiovascular Mortality Among US Counties, 2014 to 2018

Safi U. Khan, Zulqarnain Javed, Ahmad N. Lone, Sourbha S. Dani, Zahir Amin, Sadeer G. Al-Kindi, Salim S. Virani, Garima Sharma, Ron Blankstein, Michael J. Blaha, Miguel Cainzos-Achirica, Khurram Nasir

doi : 10.1161/CIRCULATIONAHA.121.054516

Circulation. 2021;144:1272–1279

Substantial differences exist between United States counties with regards to premature (<65 years of age) cardiovascular disease (CVD) mortality. Whether underlying social vulnerabilities of counties influence premature CVD mortality is uncertain.

Buy The Package and View The Article Online

Premature Cardiovascular Mortality in the United States: Who Will Protect the Most Vulnerable Among Us?

Apoorva Gangavelli, Alanna A. Morris

doi : 10.1161/CIRCULATIONAHA.121.056658

Circulation. 2021;144:1280–1283

Buy The Package and View The Article Online

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Milton Packer, Javed Butler, Faiez Zannad, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J. Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass, Michel Komajda, Alan Miller, Steen Pehrson, John R. Teerlink, Sven Schnaidt, Cordula Zeller, Janet M. Schnee, Stefan D. Anker, for the EMPEROR-Preserved Trial Study Group

doi : 10.1161/CIRCULATIONAHA.121.056824

Circulation. 2021;144:1284–1294

Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events.

Buy The Package and View The Article Online

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Renato D. Lopes, Celestia S. Higano, Susan F. Slovin, Adam J. Nelson, Robert Bigelow, Per S. Sørensen, Chiara Melloni, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson, Deepak L. Bhatt, Noel W. Clarke, Tine K. Olesen, Belinda T. Doyle-Olsen, Henriette Kristensen, Lauren Arney, Matthew T. Roe, John H. Alexander, and on behalf of the PRONOUNCE Study Investigators

doi : 10.1161/CIRCULATIONAHA.121.056810

Circulation. 2021;144:1295–1307

The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial.

Buy The Package and View The Article Online

Role of Venous Endothelial Cells in Developmental and Pathologic Angiogenesis

Heon-Woo Lee, Yanying Xu, Liqun He, Woosoung Choi, David Gonzalez, Suk-Won Jin, Michael Simons

doi : 10.1161/CIRCULATIONAHA.121.054071

Circulation. 2021;144:1308–1322

Angiogenesis is a dynamic process that involves expansion of a preexisting vascular network that can occur in a number of physiological and pathological settings. Despite its importance, the origin of the new angiogenic vasculature is poorly defined. In particular, the primary subtype of endothelial cells (capillary, venous, arterial) driving this process remains undefined.

Buy The Package and View The Article Online

Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease

Paolo Calabrò, Felice Gragnano, Giampaolo Niccoli, Rossella Marcucci, Marco Zimarino, Carmen Spaccarotella, Giulia Renda, Giuseppe Patti, Giuseppe Andò, Elisabetta Moscarella, Massimo Mancone, Arturo Cesaro, Gennaro Giustino, Raffaele De Caterina, Roxana Mehran, Davide Capodanno, Marco Valgimigli, Stephan Windecker, George D. Dangas, Ciro Indolfi, Dominick J. Angiolillo, on behalf of the Working Group of Interventional Cardiology and the Working Group of Thrombosis of the Italian Society of Cardiology

doi : 10.1161/CIRCULATIONAHA.121.054305

Circulation. 2021;144:1323–1343

Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients.

Buy The Package and View The Article Online